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Here, we extended our findings from a genome-wide association
study of the euphoric response to d-amphetamine in healthy hu-
man volunteers by identifying enrichment between SNPs associ-
ated with response to d-amphetamine and SNPs associated
with psychiatric disorders. We found that SNPs nominally associ-
ated (P ≤ 0.05 and P ≤ 0.01) with schizophrenia and attention
deficit hyperactivity disorder were also nominally associated with
d-amphetamine response. Furthermore, we found that the source
of this enrichment was an excess of alleles that increased sensi-
tivity to the euphoric effects of d-amphetamine and decreased
susceptibility to schizophrenia and attention deficit hyperactivity
disorder. In contrast, three negative control phenotypes (height,
inflammatory bowel disease, and Parkinson disease) did not show
this enrichment. Taken together, our results suggest that alleles iden-
tified using an acute challenge with a dopaminergic drug in healthy
individuals can be used to identify alleles that confer risk for psychi-
atric disorders commonly treated with dopaminergic agonists and
antagonists. More importantly, our results show the use of the
enrichment approach as an alternative to stringent standards for
genome-wide significance and suggest a relatively novel approach
to the analysis of small cohorts in which intermediate phenotypes
have been measured.
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Genome-wide association studies (GWAS) implicitly assumethat all SNPs in the genome are equally likely to be causal,
although most SNPs are unlikely to have any functional con-
sequences. Studies from our groups and others have shown the
use of incorporating prior information about SNPs into the ge-
netic analysis of complex traits, including autism and bipolar
disorder (1–6). These studies have shown that there is an en-
richment of SNPs with functional consequences (e.g., expression
quantitative trait loci) among SNPs modestly associated with a
broad spectrum of complex traits.
We recently conducted, to our knowledge, the first GWAS of an
intermediate pharmacogenetic phenotype, namely the acute sub-
jective response to a drug of abuse, d-amphetamine, in a sample of
381 healthy human volunteers (7). We identified only one genome-
wide significant association, and no replication samples were
available; thus, the results were difficult to interpret. In the present
study, we sought to further interrogate the numerous nominally
significant associations from our d-amphetamine response GWAS.
We hypothesized that nominally significant associations would be
mostly false positives but also, would be enriched for true positives.
Amphetamine produces its subjective and behavioral effects in
part by increasing synaptic levels of dopamine (8). We took
advantage of prior GWASs for psychiatric disorders to identify
a subset of SNPs that showed nominal association with both
amphetamine response and psychiatric disorders in which do-
paminergic signaling is also hypothesized to play an important
role. We predicted that, if these different phenotypes had shared
susceptibility alleles, then we would observe more overlapping
SNPs than expected by chance. We also predicted that such an
enrichment phenomenon would have a consistent direction.
Results
SNPs Associated with the Euphoric Response to d-Amphetamine Are
Enriched for SNPs Associated with Protection from Schizophrenia. In
the enrichment analysis, we observed a statistically significant
enrichment of schizophrenia-associated SNPs from the Genetic
Association Information Network (GAIN) sample among our
associations with amphetamine response at both the P ≤ 0.01
and P ≤ 0.05 thresholds (empirical P = 0.043 and P = 0.005
respectively (Fig. 1). Fig. 2 displays the results from the enrich-
ment analysis of schizophrenia-associated SNPs from Psychiatric
Genomics Consortium phase 1 (PGC1), which includes the
GAIN dataset as well as a number of additional cohorts. Repli-
cating the results that we initially observed in the GAIN sample,
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we found a significant enrichment of schizophrenia-associated
SNPs among the SNPs associated with amphetamine response at
both the P ≤ 0.01 and P ≤ 0.05 thresholds (empirical P = 0.007
and P = 0.033, respectively) (Fig. 2A).
We hypothesized that, if the enrichment phenomena were
based on a real biological phenomenon, there would be a consistent
relationship between the direction of the effect (positive or
negative) of alleles on risk for schizophrenia and sensitivity to
the euphoric effects of amphetamine. To test this hypothesis, we
performed two analyses: one analysis in which alleles that in-
creased the risk for schizophrenia also increased amphetamine
response (concordant) and one analysis in which alleles that
increased the risk for schizophrenia decreased amphetamine
response (discordant). This analysis could not be performed in the
GAIN schizophrenia study, because odds ratios were unavailable.
In the PGC1 schizophrenia dataset, we found that 239 of 380
SNPs (62.9%) that constituted the enriched set at the P ≤ 0.01
threshold had discordant direction between the two datasets.
Although modest, this enrichment was unambiguously significant
compared with the permutation-derived expected distribution
of SNPs with discordant direction alleles (empirical P = 0.004)
(Fig. 2B). No such enrichment was seen for 141 concordant SNPs
(empirical P = 0.269) (Fig. 2B). A similar result was observed
when using the P ≤ 0.05 threshold (empirical P = 0.017 for
discordant SNPs and empirical P = 0.440 for concordant SNPs)
(Fig. 2B). Therefore, the significant enrichment of schizophrenia-
associated SNPs among amphetamine-associated SNPs was driven
by discordant alleles.
SNPs Associated with the Euphoric Response to d-Amphetamine Are
Enriched for SNPs Associated with Protection from Attention Deficit
Hyperactivity Disorder. We observed significant enrichment of
attention deficit hyperactivity disorder (ADHD)-associated
SNPs among the SNPs associated with amphetamine response at
both the P ≤ 0.01 and P ≤ 0.05 thresholds (empirical P = 0.011
and P = 0.038, respectively) (Fig. 3A). As with schizophrenia, we
hypothesized that there would be a consistent direction of the
effects among the overlapping SNPs. Indeed, we found that 114
of 197 overlapping SNPs (57.9%, P ≤ 0.01 threshold) (Fig. 3A)
had discordant effects (empirical P = 0.011) (Fig. 3B). No such
enrichment was seen for concordant SNPs (empirical P =
0.087) (Fig. 3B). Thus, alleles that decreased risk for ADHD







































Fig. 1. SNPs associated with the
euphoric response to d-amphet-
amine are enriched for SNPs as-
sociated with schizophrenia in the
GAIN schizophrenia sample. A
schematic representation of the
enrichment analysis is shown in
Left. There was a significant en-
richment of SNPs nominally asso-
ciated with schizophrenia among
SNPs nominally associated with
the euphoric response to d-am-
phetamine; the enrichment was
significant with P value thresholds of (Center) P ≤ 0.01 and (Right) P ≤ 0.05. The black dots represent the number of overlapping SNPs. The histograms
represent the null distribution of overlapping SNPs generated from 1,000 random permutations of the amphetamine data. SCZ, schizophrenia. *P < 0.05.
B
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Fig. 2. SNPs associated with the euphoric response
to d-amphetamine are enriched among SNPs asso-
ciated with protection from schizophrenia. A shows
a schematic representation of the enrichment analy-
sis. There was a significant enrichment of SNPs that
were nominally associated with schizophrenia from
the PGC1 Schizophrenia sample among SNPs nomi-
nally associated with the euphoric response to d-
amphetamine; the enrichment was significant with
P value thresholds of (Center) P ≤ 0.01 or (Right) P ≤
0.05. The black dots represent the observed number
of overlapping SNPs. The histograms represent the
null distribution of overlapping SNPs generated
from 1,000 random permutations of the amphet-
amine data. B shows the same analysis as A, except
that SNPs were only considered if they were (Upper)
concordant in direction or (Lower) discordant in di-
rection. These results indicate that the discordant
SNPs are responsible for the enrichment observed
in A. AMPH, d-amphetamine; SCZ, schizophrenia.
*P < 0.05.






were associated with increased amphetamine response. Similar
results were observed at the P ≤ 0.05 threshold (empirical P =
0.038 for discordant SNPs and empirical P = 0.394 for concordant
SNPs) (Fig. 3B).
SNPs Associated with the Euphoric Response to d-Amphetamine Are
Not Enriched for SNPs Associated with Three Negative Control
Phenotypes. We considered the possibility that enrichment might
be caused by linkage disequilibrium (LD) structure or some un-
expected artifact not properly accounted for by the permutation
analysis and thus, would be observed in any large GWAS. To
evaluate this possibility, we examined enrichment in three negative
control phenotypes for which large samples were available. We
found no significant enrichment of SNPs associated with height at
the P ≤ 0.01 or P ≤ 0.05 thresholds (Fig. 4A) (P = 0.518 and P =
0.441, respectively). Similarly, there was no significant enrichment
of SNPs associated with inflammatory bowel disease at the P ≤
0.01 threshold (Fig. 4B) (empirical P = 0.391); data for in-
flammatory bowel disease at the P ≤ 0.05 threshold were not
available. Additionally, we saw no enrichment for Parkinson
disease-associated SNPs at either the P ≤ 0.01 or P ≤ 0.05
thresholds (Fig. 4C) (P = 0.126 and P = 0.836, respectively).
In terms of directionality in the negative control samples, we
found no significant enrichment of concordant or discordant
SNPs in the Parkinson disease dataset. We were unable to obtain
directional information for the height and inflammatory bowel
disease datasets. However, we were able to obtain directional
information for a Crohn disease GWAS dataset that largely over-
laps with a subset of the inflammatory bowel disease sample (9).
Using that dataset, we observed no significant overall enrichment
and no significant enrichment of concordant or discordant SNPs.
Similar Results Are Observed When Imputed SNPs from the
Amphetamine Response Dataset Are Excluded. All results pre-
sented were derived from analyses using amphetamine response
data that consist of a mixture of directly genotyped and imputed
SNPs. To assess the possibility that an artifact related to imputation
had caused the observed enrichment, we conducted similar
analyses that were restricted to directly genotyped SNPs in the
amphetamine response dataset; these results were not meaningfully
different (Fig. S1). Thus, these results do not seem to be an artifact
of imputation.
Enrichment of Schizophrenia and ADHD-Associated SNPs Is Observed
in Replication Samples. To replicate our findings of enrichment for
schizophrenia associated SNPs in the GAIN and PGC1 datasets, we
obtained an additional replication dataset [Swedish schizophrenia
sample (10)] and repeated our analyses in the replication sample
alone and the combined meta-analysis sample (PGC1 schizophre-
nia + Swedish schizophrenia). When considering only the Swedish
schizophrenia sample, we observed borderline significant enrich-
ment at the P ≤ 0.05 threshold (P = 0.067); when we performed the
same analysis in the meta-analysis sample (PGC1 schizophrenia +
Swedish schizophrenia), we found that the strength of enrichment
improved (P = 0.021) compared with the same analysis in the
PGC1 schizophrenia sample alone. We also found that the strength
of enrichment among the discordant SNPs was slightly improved in
this larger meta-analysis sample (P = 0.016) compared with the
results from the PCG1 schizophrenia data.
Similarly, we were able to replicate our findings in a newer
ADHD replication dataset [Psychiatric Genomics Consortium
phase 2 (PGC2) ADHD] using the P ≤ 0.05 threshold. In this case,
we did not observe a significant enrichment when using only the
ADHD replication dataset (PGC2 ADHD); however, we did ob-
serve a nearly significant enrichment of discordant direction SNPs
(P = 0.060). Similarly, in the meta-analysis sample (PGC1 ADHD +
PGC2 ADHD), we observed an even more significant enrichment
of discordant direction SNPs (P = 0.010) in the meta-analysis
sample compared with the PCG1 ADHD sample alone.
SNPs Associated with the Increased Euphoric Response to
d-Amphetamine Are Enriched for SNPs That Confer Protection from
Bipolar Disorder. We hypothesized that SNPs associated with the
euphoric response to amphetamine may also be enriched for SNPs
A
B
Fig. 3. SNPs associated with the euphoric response
to d-amphetamine are enriched among SNPs asso-
ciated with protection from ADHD. A shows a sche-
matic representation of the enrichment analysis.
There was a significant enrichment of SNPs that
were nominally associated with ADHD from the
PGC1 ADHD sample among SNPs nominally associ-
ated with the euphoric response to d-amphetamine.
The results were (Center) significant at the P ≤ 0.01
threshold and (Right) borderline significant at the
P ≤ 0.05 threshold. The black dots represent the
observed number of overlapping SNPs. The histo-
grams represent the null distribution of overlapping
SNPs generated from 1,000 random permutations of
the amphetamine data. B shows the same analysis
as A, except that SNPs were only considered if
they were (Upper) concordant in direction or (Lower)
discordant in direction. These results indicate that the
discordant SNPs are responsible for the enrichment
observed in A. AMPH, d-amphetamine. *P < 0.05.
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associated with bipolar disorder. We did not observe an overall
significant enrichment (Fig. S2). However, when we stratified
SNPs by concordant vs. discordant, we again observed a signif-
icant enrichment of discordant SNPs at both the P ≤ 0.01 and
P ≤ 0.05 thresholds (empirical P = 0.018 and P = 0.045, re-
spectively) (Fig. S2).
A Subset of the SNPs That Are Associated with the Euphoric Response
to d-Amphetamine Are Enriched for SNPs That Confer Protection from
Both Schizophrenia and ADHD. We were interested in testing
whether any of the SNPs that overlapped with d-amphetamine
response were shared with both schizophrenia and ADHD.
Shared SNPs would suggest shared biology, potentially related
to dopaminergic function. We found suggestive evidence for
enrichment of SNPs shared among all three phenotypes (am-
phetamine response, schizophrenia, and ADHD; P = 0.062) (Fig.
S3). When we tested only concordant SNPs (increased amphet-
amine response and increased risk for both schizophrenia and
ADHD) and discordant SNPs (increased amphetamine response
and decreased risk for both schizophrenia and ADHD), we only
found significant enrichment for discordant SNPs (P = 0.029) (Fig.
S3), similar to results for schizophrenia and ADHD. This analysis
identified a small subset of SNPs that is likely to contribute to
enhanced euphoric responses to d-amphetamine and decreased
risk for schizophrenia and ADHD. This result is interesting in light
of the results from the PGC Cross-Disorder group, which showed
no genetic overlap between schizophrenia and ADHD (6).
Discussion
Our results show that SNPs associated with response to a dopa-
minergic drug challenge (d-amphetamine) are enriched for SNPs
associated with psychiatric disorders that are treated with do-
pamine agonists (ADHD) and antagonists (schizophrenia). Rather
than identifying a few SNPs with a high degree of statistical con-
fidence, our method is intended to identify a heterogeneous col-
lection of SNPs that is made up of both true- and false-positive
associations. We show that this enrichment was caused by alleles
that increased the euphoric response to amphetamine and de-
creased the risk for both schizophrenia and ADHD. In contrast, no
enrichment was observed for concordant SNPs or any non-
psychiatric phenotypes. We also showed that the results were
not an artifact of imputation and that these effects could be
replicated in multiple samples.
Of the theories regarding the underlying mechanisms for
schizophrenia, the so-called dopamine hypothesis has been the
most enduring (11, 12). Although this theory is still under debate
(13, 14), several lines of evidence lend credence to the hypoth-
esis. For example, the efficacy of typical antipsychotic drugs is
almost linearly related to their affinity for the dopamine D2
receptor (15). Additionally, when high doses of amphetamine
are ingested for a protracted period, psychotic symptoms can
develop (16). Several studies have shown increased striatal do-
pamine release in response to a d-amphetamine challenge in
schizophrenics and consequently, a worsening of symptoms (17,
18). Our study adds genetic evidence to support the dopami-
nergic hypothesis of schizophrenia using a cohort of healthy
volunteers carefully screened against Axis I psychiatric disorders.
A dopamine hypothesis of ADHD has also been proposed and
challenged (19, 20). ADHD is often treated with methylpheni-
date or amphetamine products (d-amphetamine, mixed amphet-
amine salts, or lisdexamfetamine) (21). The therapeutic effects of
these drugs are believed to be caused by their ability to increase
the synaptic availability of dopamine. Interestingly, our results
suggest that insensitivity to a drug that is used to treat ADHD
might be a genetic risk factor for ADHD; however, it is important
to note that we examined sensitivity to the euphoric effects of
amphetamine and not sensitivity to its therapeutic effects. Our
results are consistent with studies that have shown a protective
effect from substance use disorders in stimulant-treated adoles-
cents with ADHD (22, 23).
A puzzling feature of our results is that we saw enrichment of
protective alleles for both schizophrenia and ADHD among our
top associations with acute amphetamine response, whereas
a simplistic understanding of these disorders suggests different
types of dopamine dysregulation: excess dopamine in schizo-
phrenia vs. dopamine deficit in ADHD. There is mixed evidence
for shared genetic risk for schizophrenia and ADHD. A higher
incidence of ADHD symptoms has been observed among relatives
of schizophrenic patients compared with healthy controls (24) as
well as increased risk for schizophrenia among relatives of in-
dividuals with ADHD (25). A recent polygenic risk score analysis
identified shared genetic susceptibility between schizophrenia
and ADHD (26). However, another recent study did not identify
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Fig. 4. SNPs associated with the euphoric response
to d-amphetamine (P ≤ 0.01 and P ≤ 0.05) do not
show enrichment among SNPs associated with height,
inflammatory bowel disease, or Parkinson disease. We
performed these analyses as a negative control. A
shows the results for the height enrichment analysis.
Results from the P ≤ 0.01 threshold are shown in Left,
and results from the P ≤ 0.05 threshold are shown in
Right. The black dots represent the observed count of
height-associated SNPs among associations with
d-amphetamine response. The histograms represent
the null distribution of overlapping SNPs generated
from 1,000 random permutations of the amphet-
amine data. B shows the results for the inflammatory
bowel disease enrichment analysis [P ≤ 0.01 thresh-
old; P ≤ 0.05 results were not available from In-
ternational Inflammatory Bowel Disease Genetics
Consortium (IIBDGC)]. The black dot represents the
observed count of inflammatory bowel disease-asso-
ciated SNPs among associations with d-amphetamine
response. The histogram represents the null distri-
bution of overlapping SNPs generated from 1,000
random permutations of the amphetamine data.
None of these results were significant. C shows the
results for the Parkinson disease enrichment analysis.
Results from the P ≤ 0.01 threshold are shown in Left, and results from the P ≤ 0.05 threshold are shown in Right. The black dots represent the observed count
of Parkinson disease-associated SNPs among associations with d-amphetamine response. The histograms represent the null distribution of overlapping SNPs
generated from 1,000 random permutations of the amphetamine data. GIANT, Genetic Investigation of Anthropometric Traits.






significant polygenic risk overlap for schizophrenia and ADHD
(6), and a different recent study found no significant genetic
correlation estimated from SNP heritabilities for the two dis-
orders (27). Our approach is different, because we are examining
only the subset of SNPs that is associated with both amphetamine
response and these psychiatric disorders, which may explain the
discrepancy between our results and these two recent studies and
may identify another advantage of our approach.
These data suggest that our acute amphetamine response
phenotype may be viewed as an endophenotype for schizophre-
nia and ADHD. Whereas prior definitions of endophenotypes
have focused on cosegregation of the putative endophenotype
and the disease phenotype, we examined associations at SNPs
throughout the genome to establish a genetic link between am-
phetamine response with both schizophrenia and ADHD. Our
sample was specifically screened to exclude individuals with Axis
I disorders, which should have depleted the number of risk
alleles present in this population. The results suggest a relatively
novel approach to the empirical validation of endophenotypes.
Comorbidity of ADHD and bipolar disorder has been repor-
ted in the literature (28), and thus, we considered the possibility
of enrichment of bipolar disorder-associated SNPs and am-
phetamine response-associated SNPs. Although we did not ob-
serve overall enrichment, we did observe directionality, with
significant enrichment of discordant SNPs at two P value thresh-
olds. These results suggest that, in addition to schizophrenia and
ADHD, the acute amphetamine response phenotype may also
be an endophenotype for bipolar disorder (29).
We initially conceived of the acute response to amphetamine
as an intermediate phenotype for drug abuse. However, our results
suggest that acute drug challenge phenotypes may be useful in
identifying SNPs that are functionally relevant to psychiatric dis-
orders. Based on this study, it may be reasonable to ask whether
sensitivity to therapeutic drugs (or drugs that cause worsening of
symptoms) may uncover alleles that confer risk or protection for
other disorders. Whether acute amphetamine response is indeed
a useful intermediate phenotype for drug abuse or other disorders
may be determined in future studies; related research examining the
euphoric response to alcohol has proven fruitful (30–34).
Our amphetamine response GWAS was based on a relatively
small sample. Lack of power is likely to contribute to the inability to
achieve signals that survive multiple testing corrections in the GWAS
of psychiatric phenotypes (35). By taking an enrichment approach,
we were able to capitalize on associations that did not meet stringent
genome-wide significance criteria but were nominally associated with
amphetamine response. Our results suggest that the enrichment
approach is complementary to the traditional GWAS approach and
a valuable secondary analysis. In contrast to GWAS, which aims to
identify specific SNPs, the power of our method is that it can draw
biological inferences from a heterogeneous set of SNPs composed of
both true and false positives. However, this method is unable to
distinguish between these two categories.
Although our study is not without limitations, we considered
several alternative explanations for our observations, but none
proved credible. One possibility was that results from any two
GWAS may overlap because of LD patterns. By using permu-
tation, we preserved the LD structure among the SNPs being
tested, which should guard against such a phenomenon. This
possibility is further addressed by the directional analyses and our
use of negative control phenotypes. We considered the possibility
that the enrichment that we observed was driven by functional
brain SNPs (e.g., expression quantitative trait loci) that would be
enriched for any brain disease. However, we saw no enrichment
for Parkinson disease-associated SNPs, suggesting that our results
are specific to schizophrenia and ADHD; the results from our
directional analyses of schizophrenia and ADHD further dispute
the possibility that the overlapping SNPs are important for all
brain diseases. We were also concerned that artifacts caused by
imputation could bias our results. However, we observed similar
results when we considered only SNPs that were directly geno-
typed in the amphetamine response sample; permutation should
further guard against any such artifacts (Fig. S1). Our results are
further strengthened by the fact that they were observed in
multiple datasets.
By examining our GWAS results through the lens of enrich-
ment, we were able to interrogate results that do not meet
stringent criteria for statistical significance. Our results suggest
that alleles identified using an acute drug challenge can be used
to identify alleles that influence risk for psychiatric disorders.
Our results also support the dopamine hypotheses of schizophrenia
and ADHD. Ultimately, this study shows that additional sec-
ondary analyses of GWAS results may provide new insights into
the biology of psychiatric disorders. These results also suggest a
useful and generalizable method for the genetic analysis of
modestly sized intermediate phenotypes that are unlikely to
yield genome-wide significant results and for which replication
samples are not typically available.
Materials and Methods
Genetics of Amphetamine Dataset. Study details are provided in the work by
Hart et al. (7). This study was approved by the Institutional Review Board of
The University of Chicago and was carried out in accordance with the Hel-
sinki Declaration of 1975. Briefly, 381 healthy volunteers attended three
separate 4-h sessions, during which they received d-amphetamine (placebo,
10 mg, or 20 mg) under double blind conditions and subjective self-report
questionnaires at regular intervals: the Profile of Mood States (36), Drug Effects
Questionnaire (37), and Addiction Research Center Inventory (38). Sparse factor
analysis (39) was used to reduce the dimensionality of the phenotype data to
a small number of factors that explained both drug response and baseline
characteristics of the sample. For the present study, we limited our analyses to
the 10-mg [d-amphetamine] response factor. This factor, hereafter referred to as
amphetamine response, was one of themost interpretable factors, reflecting the
subjective euphoric response to amphetamine, and it showed the strongest as-
sociation signal (7). Subjects were genotyped using Affymetrix 6.0 arrays. Im-
putation was performed using the HapMap3 and 1000 Genomes reference
panels (40, 41). Self-reported ancestry was confirmed by analysis with the
SMARTPCA component of EIGENSOFT (42). The sample used in the current
study was restricted to participants of European ancestry (n = 325). After
quality control and imputation, 5,974,669 SNPs were available for analysis.
The samples used for the enrichment analysis are shown in Table S1; addi-
tional details are given in the SI Materials and Methods.
Data Preparation. In the Genetics of Amphetamine dataset, SNPs with minor
allele frequencies < 0.01 were removed. Genotypes were converted into
PLINK format with GTOOL (www.well.ox.ac.uk/∼cfreeman/software/gwas/
gtool.html) with a threshold of 0.8 specified; markers with missing rates >
10% were excluded. The amphetamine response phenotype was permuted
1,000 times using the “make-perm-pheno” command in PLINK (43), and as-
sociation testing was run with each of these 1,000 permuted phenotypes
with the PLINK “assoc” command. The numbers of SNPs available for the
enrichment analysis are listed in Table S2.
Enrichment Analysis. The number of SNPs that overlapped between the
amphetamine response results and the results for each of the pheno-
types described above was recorded (for both the P ≤ 0.01 and P ≤ 0.05
thresholds). Next, the number of overlapping SNPs in each permuted
dataset (n = 1,000) was recorded, yielding the expected null distribu-
tion. The empirical P value was computed as the fraction of permuta-
tions where the number of overlapping SNPs matched or exceeded the
observed count. A statistically significant enrichment was defined as an
enrichment P value < 0.05 (i.e., less than 50 permutations were found
with a greater number of overlapping SNPs).
Directionality Analysis. For the SNPs that overlapped between the phenotypes
examined in the enrichment analyses described above, we examined the
direction of the effect in both the amphetamine response and the second
phenotype. The signs of the logistic regression β-coefficients [i.e., ln(odd
ratio)] were used to denote directionality. The Z scores from the PGC1 ADHD
results were used to denote directionality of the association, with Z score >
0 corresponding to odds ratio > 1. The signs of the β-coefficients or Z scores
were flipped if the PGC reference allele did not match the reference allele in
the amphetamine response dataset. We recorded the number of concordant
SNPs (positive in both samples or negative in both samples) and the number
of discordant SNPs (positive in one sample and negative in the other sample)
in the real and permuted datasets. This procedure generated the expected
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null distribution of concordant alleles (e.g., alleles associated with risk as
well as heightened response to amphetamine) and the expected null dis-
tribution of discordant alleles. Excluding strand ambiguous SNPs had no
effect on our results. The empirical P value was computed as the proportion
of permutations where the number of overlapping SNPs matched or
exceeded the count observed in the real data.
Replication Analyses. Enrichment and directionality analyses were performed
as described above in the replication samples alone (Swedish schizophrenia
study and PGC2 ADHD) and the combined meta-analysis samples (PGC1
schizophrenia + Swedish schizophrenia and PGC1 ADHD + PGC2 ADHD).
Meta-analysis was performed with the “meta-analysis” command in PLINK.
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